ED
TCRT icon

Exane Derivatives’s Alaunos Therapeutics TCRT Stock Holding History

Exane Derivatives’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-271
Closed -$26.5K – 916
2022
Q1 		$26.5K Buy
+271
New +$34.8K 0.01% 637
2021
Q3 		– Sell
-302
Closed -$109K – 1075
2021
Q2 		$109K Hold
302
– – 0.02% 529
2021
Q1 		$163K Buy
302
+227
+303% +$141K 0.05% 330
2020
Q4 		$28.3K Buy
+75
New +$29.8K 0.01% 499

Other funds holding TCRT

MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Exane Derivatives's TCRT Position: Q2 2022 in Review

Exane Derivatives sold out of Alaunos Therapeutics (TCRT) in Q2 2022, closing a stake of 271 shares — an estimated $26.5K sold.

Exane Derivatives first reported a position in TCRT in Q4 2020 and held it in 4 quarters. The position peaked at $163K in Q1 2021. 124 funds tracked by Wall St. Rank hold TCRT as of Q2 2022.

  • Exane Derivatives reported no remaining Alaunos Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Exane Derivatives sold 271 Alaunos Therapeutics shares in Q2 2022, an estimated $26.5K.
  • Exane Derivatives first reported a position in Alaunos Therapeutics in Q4 2020 and held it in 4 quarters.
  • Exane Derivatives's Alaunos Therapeutics position peaked at $163K in Q1 2021.
  • 124 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.